186 related articles for article (PubMed ID: 34452863)
21. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
22. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.
Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM
Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009
[TBL] [Abstract][Full Text] [Related]
23. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
24. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
[TBL] [Abstract][Full Text] [Related]
25. MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
Iida S; Ishida T; Miyamoto T; Teramukai S; Shirai H; Kanamori R; Tajima Y; Crawford B; Yi J; Teshima T
Int J Hematol; 2022 Sep; 116(3):411-422. PubMed ID: 35551631
[TBL] [Abstract][Full Text] [Related]
26. Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma.
Koo J; Teusink-Cross A; Davies SM; Jodele S; Dandoy CE
Pediatr Blood Cancer; 2021 Nov; 68(11):e29319. PubMed ID: 34490994
[TBL] [Abstract][Full Text] [Related]
27. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.
Kim SS; Renteria AS; Steinberg A; Banoff K; Isola L
Cytotherapy; 2014 Nov; 16(11):1584-1589. PubMed ID: 24927717
[TBL] [Abstract][Full Text] [Related]
30. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
31. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
Ri M; Matsue K; Sunami K; Shimazaki C; Hayashi A; Sunaga Y; Sasaki T; Suzuki K
Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
35. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
36. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
37. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
[TBL] [Abstract][Full Text] [Related]
39. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
40. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]